Abstract: A method and kit for the immunotyping of T lymphocyte development subgroups. The method for the immunotyping of T lymphocyte development subgroups comprises: taking antibodies with different fluorescence labels, mixing same with a to-be-detected sample, performing incubating, and then performing detection by means of flow cytometry to obtain detection data, wherein the antibodies comprise: an anti-CD45 antibody, an anti-CD3 antibody, an anti-CD4 antibody, an anti-CD8 antibody, an anti-CD25 antibody, an anti-CD127 antibody, an anti-CD45RO antibody, an anti-CD28 antibody, an anti-CD197 antibody and an anti-CD95 antibody. According to the present invention, more comprehensive immunotyping of T lymphocyte development subgroups is achieved, few to-be-detected samples are required, operation is easy, the required time is shorted, and the accuracy is high.

Abstract: An oligosaccharide vaccine for specific prevention of fungal infections and a method for preparing the same are provided. The vaccine is formed by conjugating a sulfhydrylated protein with oligosaccharide. The sulfhydrylated protein is formed by introducing a sulfhydryl group (—SH) to a carrier protein containing a primary amino group (—NH2), and then is conjugated with the oligosaccharide to form the oligosaccharide vaccine under the binding action of a bridging agent. The carrier protein is a non-humanized protein, and the oligosaccharide is a chitosan oligosaccharide mixture and/or chitin oligosaccharide mixture. The vaccine has strong immunogenicity, can activate Th17 cell immunity, and can recognize and protect infections caused by fungi.

Abstract: The present application relates to a fusion protein and use thereof. The fusion protein comprises RdCVF and a signal peptide, wherein the signal peptide is an amino acid sequence set forth in any one of SEQ ID NOs: 27-31 and 33. The present application also relates to an isolated nucleic acid molecule comprising a) a polynucleotide encoding RdCVF and b) a polynucleotide encoding a signal peptide. The present application also provides a vector, a cell, and a pharmaceutical composition containing the nucleic acid molecule, as well as medical use thereof. The fusion protein and/or isolated nucleic acid molecule described herein can effectively increase the secretion of RdCVF.